ReviewClinical medicine (London, England)2020
Post renal-transplant malignancy surveillance.
Review in Clinical medicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases.Current oncology (Toronto, Ont.) · 2023Pooled it
- Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation.World journal of transplantation · 2026Review
- Solid masses arising in transplanted kidneys.Abdominal radiology (New York) · 2026Review
- Incidence and outcomes of malignancies in renal transplant recipients: a 57-year single-center experience.World journal of urology · 2026Article
- Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients.Journal of health economics and outcomes research · 2026Article
- Article
- Epidemiological Overview of Colorectal Cancer in Kidney Transplant Recipients: A Systematic Review.Cancers · 2025Review
- Primary care for recipients of kidney transplants.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Providing care for kidney transplant recipients: An overview for generalists.World journal of nephrology · 2025Review
- Retrospective assessment of the frequency of cancer in the population of kidney transplant recipients - the experience of two transplant centers.Frontiers in oncology · 2025Article
- Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient.Frontiers in oncology · 2025Article
- Cancer Screening in Renal Transplant Recipients: Real-World Data.World journal of oncology · 2024Article
- [Urogenital tumors following kidney transplantation-monocentric analysis of incidences and overview of urological preventive measures].Urologie (Heidelberg, Germany) · 2024Article
- A Rare Case of Donor-Derived Renal Cell Carcinoma in a Kidney Transplant Recipient.The American journal of case reports · 2024Article
- Article
- Incidence of Malignancy and Risk Factors Associated with Kidney Transplant Patients.Galen medical journal · 2024Article
- Single-Cell RNA Sequencing of Donor-Reactive T Cells Reveals Role of Apoptosis in Donor-Specific Hyporesponsiveness of Kidney Transplant Recipients.International journal of molecular sciences · 2023Article
- Bladder paraganglioma after kidney transplantation: A case report.World journal of clinical cases · 2022Article
- Risk of malignancy in kidney transplant recipients: a nationwide population-based cohort study.BMC nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well recognised that kidney transplant recipients have an increased risk of cancers compared with the age and gender matched general population. Malignancy is one of the commonest causes of death among this cohort after cardiovascular disease. This increased risk is largely attributable to the effect of immunosuppression, which impairs T cell function, immunosurveillance and the immunological control of oncogenic viral infections. Cancer related mortality rates are also higher in solid organ transplant recipients compared with the general population. While early diagnosis may improve outcomes in these patients, cancer screening is debatable given the lack of randomised controlled trials in this cohort, and treatment is often challenging. This article reviews the epidemiology and risk factors for the development of malignancy in the post-transplant setting, as well as screening guidelines for specific malignancies of which patients are at particular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.